Innovations

 

BeGraft Plus Stent Graft System

Bentley Innomed GmbH
+49 (0) 151 141 204 26
www.bentley.global


KEY FEATURES
• Complement to the regular BeGraft stent
• Novel sandwich layer design
• For use in complex lesions
• High radial force

The BeGraft Plus stent graft system is CE Mark approved for intraluminal chronic placement in iliac and renal arteries to restore and improve the patency and treatment of aneurysms, acute perforations, and acute ruptures and fistulas.

The BeGraft Plus, the newest member of the Bentley BeGraft family, is a double stent system with expanded polytetrafluoroethylene tubing between the stents and on the outer stent. With its high radial force and remarkable flexibility, the BeGraft Plus has exclusive stent properties that make it more suitable for complex and demanding endovascular lesions.

“With BeGraft Plus, we see a new generation of covered stents that offer us new options for the treatment of aneurysm disease,” said Prof. Eric Verhoeven, MD, PhD, Head of the Department of Vascular Surgery, General Hospital Nuremberg, in Germany.

The BeGraft Plus is currently available across all CE Mark countries and will become available in several non–CE Mark countries throughout 2018. Lengths are available from 27 to 58 mm, including diameters from 5 to 10 mm. The BeGraft Plus is 7-F compatible up to a diameter of 8 mm and 8-F compatible for diameters of 9 and 10 mm.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.